CD274 and neoplasm: Consistent with this, established predictive biomarkers for patient selection—programmed cell death ligand 1 (PD-L1), microsatellite instability (MSI)-high, DNA mismatch repair deficiency (dMMR), and tumor mutational burden (TMB)—reflect a connection to T-cell biology.4